DCR-2-PBD prolongs survival in AML cell line mouse models. (A) U937 subcutaneous tumor volume of mice treated with a single injection on day 6 with either PBS (n = 8) or isotype-PBD (n = 5 both groups) or DCR-2-PBD (n = 5 both groups). (B) Survival data from mice injected with U937 subcutaneously (P = .0017 DCR-2-PBD 300 μg/kg compared with isotype-PBD 300 μg/kg). (C) Mice injected with HL-60 IV then treated day 7 with PBS (n = 6), isotype-PBD (n = 8), or DCR-2-PBD (n = 8) (P = .0058 DCR-2-PBD vs isotype-PBD).